<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05004610</url>
  </required_header>
  <id_info>
    <org_study_id>SRB2021260</org_study_id>
    <nct_id>NCT05004610</nct_id>
  </id_info>
  <brief_title>Hypertonic Lactate After Cardiac Arrest</brief_title>
  <acronym>LATTE</acronym>
  <official_title>Hypertonic Lactate After Cardiac Arrest</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasme University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erasme University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is intended to test the hypothesis that sodium lactate infusion after resuscitation&#xD;
      from a cardiac arrest will decrease the magnitude of brain damage, as measured by the serum&#xD;
      biomarker concentration of NSE.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: In resuscitated patients after cardiac arrest, ischemic brain injury and cardiac&#xD;
      depression due to the reperfusion injury are accountable for high mortality rate and poor&#xD;
      outcome. Hypertonic sodium lactate (HSL) solutions have been proven to be safe in healthy&#xD;
      volunteers and they have shown some benefits in patients with traumatic brain injury and&#xD;
      those with myocardial ischemia and could decrease the burden of hypoxic lesions in these&#xD;
      organs. The aim of this phase II study is to investigate whether HSL administration could&#xD;
      reduce organ damage related biomarkers in serum and if the administrations of these solutions&#xD;
      is safe and feasible in resuscitated patients after cardiac arrest.&#xD;
&#xD;
      Design: an investigator initiated, randomized, controlled, open label phase II clinical trial&#xD;
      to test the safety and efficacy of the infusion of HSL in resuscitated patients after cardiac&#xD;
      arrest admitted to the hospital. After resuscitation from CA, comatose patients will be&#xD;
      screened for eligibility and randomized to receive either study treatment as HSL 0.5M&#xD;
      infusion for 24h or standard of care.&#xD;
&#xD;
      Expected outcomes: This controlled trial will assess the safety and efficacy of the 0.5 HSL&#xD;
      infusion in a cohort of comatose resuscitated patients after cardiac arrest. The results of&#xD;
      this trial may provide useful information for a larger phase III clinical trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">May 15, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serum NSE</measure>
    <time_frame>48 hours after randomization</time_frame>
    <description>NSE serum levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICU free days</measure>
    <time_frame>trough study completion, on average 30 days</time_frame>
    <description>number of days free from intensive care unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>trough study completion before hospital discharge, on average 60 days</time_frame>
    <description>mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological outcome</measure>
    <time_frame>trough study completion, 90 days after randomization</time_frame>
    <description>Neurological outcome measured by Glasgow Outcome Scale at 90 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>trough study completion, on average 60 days</time_frame>
    <description>Hospital length of stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe adverse events rate</measure>
    <time_frame>during study drug administration/day 28 or ICU discharge or death</time_frame>
    <description>Serious adverse events rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for Vasopressors</measure>
    <time_frame>through study completion, on average 14 days</time_frame>
    <description>Need for vasopressors during hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seizure rate</measure>
    <time_frame>through study completion before ICU discharge, on average 14 days</time_frame>
    <description>Seizure rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in cardiac biomarkers</measure>
    <time_frame>at randomization, 24 hours, 48 hours and 72 hours after randomization</time_frame>
    <description>Troponin I serum levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in brain biomarkers</measure>
    <time_frame>at randomization, after 24 hours, 48 hours and 72 hours</time_frame>
    <description>brain biomarkers including nfL and GFAP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in brain metabolism</measure>
    <time_frame>within 24h after randomization</time_frame>
    <description>Brain metabolism measured by PET-IRM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in brain perfusion</measure>
    <time_frame>within 24h after randomization</time_frame>
    <description>brain perfusion measured with early perfusion CT scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in echocardiographic parameters (systolic)</measure>
    <time_frame>at randomization, at 24 hours and 48 hours after randomization</time_frame>
    <description>Changes systolic cardiac function assessed by echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in echocardiographic parameters (diastolic)</measure>
    <time_frame>at randomization, at 24 hours and 48 hours after randomization</time_frame>
    <description>Changes diastolic cardiac function assessed by echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>identification of optimal perfusion pressure</measure>
    <time_frame>through study completion, on average 30 days</time_frame>
    <description>identification of optimal perfusion pressure with invasive neuromonitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>identification of optimal cerebral oxygen tension</measure>
    <time_frame>through study completion, on average 30 days</time_frame>
    <description>identification of optimal cerebral oxygen tension with invasive neuromonitoring</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Cardiac Arrest</condition>
  <condition>Ischemia Reperfusion Injury</condition>
  <condition>Anoxic Brain Injury</condition>
  <arm_group>
    <arm_group_label>standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will receive the standard of care infusion (balanced crystalloids)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>treatement group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>half molar sodium lactate infusion 15 µmol/Kg/min</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Lactate Solution</intervention_name>
    <description>continuous intravenous infusion of half-molar sodium lactate</description>
    <arm_group_label>treatement group</arm_group_label>
    <other_name>Hyperonic sodium lactate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years old&#xD;
&#xD;
          -  Sustained (&gt; 20 minutes) return of spontaneous circulation (ROSC)&#xD;
&#xD;
          -  Comatose (GCS &lt; 9)&#xD;
&#xD;
          -  Time to ROSC &gt; 15'&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Protected categories (Pregnant women, Prisoners)&#xD;
&#xD;
          -  Anticipated withdrawal of support within 24 hours&#xD;
&#xD;
          -  Traumatic cause of cardiac arrest&#xD;
&#xD;
          -  time from ROSC to inclusion &gt; 1hour&#xD;
&#xD;
          -  Inclusion in any other interventional trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Filippo Annoni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Erasme</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Filippo Annoni, MD</last_name>
    <phone>0483141483</phone>
    <email>filippo.annoni@erasme.ulb.ac.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fabio S Taccone, MD,PhD</last_name>
    <email>fabio.tacconei@erasme.ulb.ac.be</email>
  </overall_contact_backup>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 30, 2021</study_first_submitted>
  <study_first_submitted_qc>August 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2021</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sodium lactate</keyword>
  <keyword>cerebral metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Heart Arrest</mesh_term>
    <mesh_term>Reperfusion Injury</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD may be available on reasonable request to other researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

